HB Wealth Management LLC Decreases Stake in Illumina, Inc. $ILMN

HB Wealth Management LLC lowered its position in Illumina, Inc. (NASDAQ:ILMN) by 29.3% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 2,848 shares of the life sciences company’s stock after selling 1,181 shares during the period. HB Wealth Management LLC’s holdings in Illumina were worth $272,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in ILMN. Rise Advisors LLC raised its holdings in shares of Illumina by 173.6% during the 1st quarter. Rise Advisors LLC now owns 353 shares of the life sciences company’s stock worth $28,000 after acquiring an additional 224 shares during the period. Rakuten Securities Inc. raised its holdings in shares of Illumina by 290.3% during the 1st quarter. Rakuten Securities Inc. now owns 363 shares of the life sciences company’s stock worth $29,000 after acquiring an additional 270 shares during the period. Center for Financial Planning Inc. purchased a new position in shares of Illumina during the 1st quarter worth $33,000. PFS Partners LLC raised its holdings in shares of Illumina by 400.0% during the 1st quarter. PFS Partners LLC now owns 500 shares of the life sciences company’s stock worth $40,000 after acquiring an additional 400 shares during the period. Finally, Golden State Wealth Management LLC raised its holdings in shares of Illumina by 123.2% during the 1st quarter. Golden State Wealth Management LLC now owns 529 shares of the life sciences company’s stock worth $42,000 after acquiring an additional 292 shares during the period. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Illumina Price Performance

Shares of NASDAQ ILMN opened at $101.02 on Tuesday. The company has a current ratio of 1.81, a quick ratio of 1.41 and a debt-to-equity ratio of 0.66. Illumina, Inc. has a twelve month low of $68.70 and a twelve month high of $156.66. The stock has a 50 day moving average of $98.89 and a two-hundred day moving average of $90.01. The stock has a market cap of $15.53 billion, a P/E ratio of 12.79, a P/E/G ratio of 2.46 and a beta of 1.40.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, July 31st. The life sciences company reported $1.19 earnings per share for the quarter, beating analysts’ consensus estimates of $1.02 by $0.17. Illumina had a return on equity of 28.93% and a net margin of 29.36%.The company had revenue of $1.06 billion during the quarter, compared to analysts’ expectations of $1.12 billion. During the same quarter in the previous year, the business earned $0.36 earnings per share. The firm’s revenue for the quarter was down 4.8% on a year-over-year basis. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. On average, research analysts forecast that Illumina, Inc. will post 4.51 earnings per share for the current year.

Analyst Ratings Changes

ILMN has been the subject of a number of recent analyst reports. Stephens set a $110.00 price objective on Illumina and gave the stock an “overweight” rating in a research report on Monday, August 4th. Weiss Ratings reissued a “sell (d+)” rating on shares of Illumina in a research report on Saturday, September 27th. Daiwa Capital Markets downgraded Illumina from an “outperform” rating to a “neutral” rating and set a $94.00 price objective for the company. in a research report on Tuesday, August 12th. Royal Bank Of Canada set a $124.00 price objective on Illumina in a research report on Tuesday, September 2nd. Finally, Robert W. Baird boosted their price target on shares of Illumina from $84.00 to $105.00 and gave the stock a “neutral” rating in a research note on Monday, July 28th. Six investment analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $123.33.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.